ArticleInternational journal of molecular sciences2025
Is PTEN rs397510595 an Unexpected Guardian in Canine Mammary Neoplasia?
Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite steps having been taken to study the influence of genetic polymorphisms in canine mammary neoplasia, the knowledge of their relevance is still incipient compared to the knowledge of human breast cancer. Among tumor suppressor genes, PTEN plays a pivotal role in carcinogenesis; however, the contribution of its constitutional variants to the biology of canine mammary neoplasia remains poorly understood. This observational study assessed the association between PTEN SNPs rs397510595 and rs397513087, genotyped from peripheral blood, and the clinicopathological features, including survival, in a cohort of 206 female dogs with mammary neoplasia. The minor A allele of rs397510595 was present in 17.5% of the population. Carriers of the variant allele were more frequently diagnosed at a late age ≥ 11 years, displayed a complete absence of vascular invasion, and exhibited significantly longer overall survival (mean 22.2 vs. 19.5 months). The SNP rs397513087 did not show a significant association with clinicopathological features or survival. Our data suggests that SNP rs397510595 of the PTEN gene is a putative protective factor for developing canine mammary neoplasia at an early age and might be used as a biomarker for prognostic assessment in dogs with malignant mammary neoplasia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.